Pfizer reports second-quarter 2012 results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012. Second-quarter 2012 revenues were $15.1 billion, a decrease of 9% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of $977 million, or 6%, and the unfavorable impact of foreign exchange of $451 million, or 3%.
Bayer reports strong business performance in the second quarter of 2012
- Details
- Category: Bayer
Sales of the Bayer Group grew by 10.0 percent in the second quarter, to EUR 10,177 million (Q2 2011: EUR 9,252 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 5.0 percent. The operating result (EBIT) fell by 41.1 percent to EUR 750 million (Q2 2011: EUR 1,273 million).
Roche reports second positive study of RoACTEMRA
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.
Amgen's second quarter 2012 revenues increased 13 percent to $4.5 billion
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced financial results for the second quarter of 2012. Key results for the quarter include: Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfolio;
AstraZeneca PLC Second quarter and half year results 2012
- Details
- Category: AstraZeneca
AstraZeneca revenue for the second quarter was $6,660 million, down 18 percent at constant exchange rates (CER). Revenue declined by 21 percent on an actual basis as a result of the negative impact of exchange rate movements.
Lilly reports second-quarter 2012 results
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2012: Worldwide revenue declined 10 percent to $5.6 billion, driven by Zyprexa patent expirations, partially offset by significant growth in other products;
Pfizer reports top-line results of study of Lyrica's effect on male reproduction
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica® (pregabalin) capsules CV Study A0081104 - Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers - demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo.
More Pharma News ...
- Novartis gains FDA approval for Afinitor® in advanced breast cancer
- Novartis second quarter results enhance future growth prospects
- Abbott reports second quarter results
- AstraZeneca to initiate a new study of BRILINTA (Ticagrelor) in patients with PAD
- GSK to acquire Human Genome Sciences for US$14.25 per share in cash
- GSK and Theravance announce regulatory submissions for FF/VI
- Boehringer Ingelheim pursuing health care innovation